More than 17.6 million American adults (about 7.5 percent) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as tree or grass pollen, and each person has their own set of problematic allergens.
Companies from across the globe provide updates on their business and pipeline progress.
Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.
Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.
Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.
After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.
Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
Companies continue to announce advancements in artificial intelligence programming as they harness the power of AI and machine learning to aid in drug discovery and development.